Advance Search
JIN Xueyan, GUO Renwei, LI Li. Research progress on clinical characteristics of heart failure with midrange ejection fraction[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 111-114, 119. DOI: 10.7619/jcmp.20201537
Citation: JIN Xueyan, GUO Renwei, LI Li. Research progress on clinical characteristics of heart failure with midrange ejection fraction[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 111-114, 119. DOI: 10.7619/jcmp.20201537
shu

Research progress on clinical characteristics of heart failure with midrange ejection fraction

  • Department of Cardiovascular, Fenyang Hospital Affiliated to Shanxi Medical University, Fenyang, Shanxi, 032200

More Information
  • Received Date: November 24, 2020
  • Available Online: March 03, 2021
  • Published Date: March 03, 2021
    Graphical Abstract
    • Abstract
  • The heart failure with midrange ejection fraction was firstly and separately proposed in 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure, from other heart failure types with ejection fraction between 30% and 50%. And this conception was officially proposed in the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2018. There are many differences between the pathogenesis and prognostic factors of different subtypes of heart failure. By analyzing the unique risk factors of different heart failure subtypes, it is possible to accurately control and treat these diseases, improve the survival rate and the quality of life. Most previous studies focused on heart failure with reduced ejection fraction and heart failure with preserved ejection fraction, with little effort concentrating on heart failure with intermediate ejection fraction. This review provided a brief overview about the clinical characteristics, treatment and prognosis of heart failure with midrange ejection fraction, so as to reduce and prevent the occurrence and development of this subtype of heart failure and improve the prognosis of patients.
    • FullText(HTML)
    • References (40)
  • [1]
    SAVARESE G, D'AMARIO D. Sex differences in heart failure[J]. Adv Exp Med Biol, 2018, 1065: 529-544.
    [2]
    PONIKOWSKI P, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Kardiologia polska, 2016, 74(10): 1037-1147.
    [3]
    中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
    [4]
    BRANCA L, SBOLLI M, METRA M, et al. Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines[J]. ESC heart failure, 2020, 7(2): 381-399. doi: 10.1002/ehf2.12586
    [5]
    GU J, YIN Z F, ZHANG H L, et al. Characteristics and outcomes of transitions among heart failure categories: a prospective observational cohort study[J]. ESC Heart Fail, 2020, 7(2): 616-625. doi: 10.1002/ehf2.12619
    [6]
    LAURITSEN J, GUSTAFSSON F, ABDULLA J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis[J]. ESC Heart Fail, 2018, 5(4): 685-694. doi: 10.1002/ehf2.12283
    [7]
    IBRAHIM N E, SONG Y, CANNON C P, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry[J]. ESC Heart Fail, 2019, 6(4): 784-792. doi: 10.1002/ehf2.12455
    [8]
    BHAMBHANI V, KIZER J R, LIMA J A C, et al. Predictors and outcomes of heart failure with mid-range ejection fraction[J]. Eur J Heart Fail, 2018, 20(4): 651-659. doi: 10.1002/ejhf.1091
    [9]
    LYU S, YU L, TAN H, et al. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China[J]. BMC Cardiovasc Disord, 2019, 19(1): 209. doi: 10.1186/s12872-019-1177-1
    [10]
    CHIONCEL O, LAINSCAK M, SEFEROVIC P M, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry[J]. Eur J Heart Fail, 2017, 19(12): 1574-1585. doi: 10.1002/ejhf.813
    [11]
    FOLLATH F, YILMAZ M B, DELGADO J F, et al. Clinical presentation, management and outcomes in the acute heart failure global survey of standard treatment (ALARM-HF)[J]. Intensive Care Med, 2011, 37(4): 619-626. doi: 10.1007/s00134-010-2113-0
    [12]
    陈建淑. 射血分数中间值心力衰竭患者NT-proBNP临床应用初步探索[D]. 兰州: 兰州大学, 2019.
    [13]
    ÖZLEK B, ÖZLEK E, AĜUȘH Z, et al. Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: a multicenter observational study[J]. Eur J Intern Med, 2019, 61: 88-95. doi: 10.1016/j.ejim.2018.11.001
    [14]
    SANTAS E, DE LA ESPRIELLA R, PALAU P, et al. Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction[J]. ESC Heart Fail, 2020, 7(3): 1007-1014. doi: 10.1002/ehf2.12683
    [15]
    张新雨. 住院射血分数中间范围的心力衰竭患者的临床特点和预后分析[D]. 郑州: 郑州大学, 2017.
    [16]
    何显菁. 不同射血分数心力衰竭患者临床特征的对比分析[J]. 实用心脑肺血管病杂志, 2019, 27(8): 96-99. https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL201908025.htm
    [17]
    STOLFO D, UIJL A, VEDIN O, et al. Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications[J]. JACC Heart Fail, 2019, 7(6): 505-515. doi: 10.1016/j.jchf.2019.03.011
    [18]
    ARDELEAN C L, PESCARIU S, LIGHEZAN D F, et al. Particularities of Older Patients with Obstructive Sleep Apnea and Heart Failure with Mid-Range Ejection Fraction[J]. Medicina-Lithuania, 2019, 55(8): 449. http://www.ncbi.nlm.nih.gov/pubmed/31394863
    [19]
    王华, 李莹莹, 柴坷, 等. 中国住院心力衰竭患者流行病学及治疗现状[J]. 中华心血管病杂志, 2019, 47(11): 865-874. doi: 10.3760/cma.j.issn.0253-3758.2019.11.004
    [20]
    ERIKSSON B, WÄNDELL P, DAHLSTRÖM U, et al. Comorbidities, risk factors and outcomes in patients with heart failure and an ejection fraction of more than or equal to 40% in primary care-and hospital care-based outpatient clinics[J]. Scand J Prim Health Care, 2018, 36(2): 207-215. doi: 10.1080/02813432.2018.1459654
    [21]
    PASCUAL-FIGAL D A, FERRERO-GREGORI A, GOMEZ-OTERO I, et al. Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure[J]. Int J Cardiol, 2017, 240: 265-270. doi: 10.1016/j.ijcard.2017.03.032
    [22]
    何柳, 杜昕, 孙玉青, 等. 不同射血分数慢性心力衰竭住院患者临床特征及院内预后情况比较[J]. 中华心力衰竭和心肌病杂志: 中英文, 2018, 2(3): 135-141. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYX202005020.htm
    [23]
    SAVARESE G, SETTERGREN C, SCHRAGE B, et al. Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design[J]. Int J Cardiol, 2020, 313: 76-82. doi: 10.1016/j.ijcard.2020.04.068
    [24]
    KAPOOR J R, KAPOOR R, JU C, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction[J]. JACC Heart Fail, 2016, 4(6): 464-472. doi: 10.1016/j.jchf.2016.02.017
    [25]
    SON M K, PARK J J, LIM N K, et al. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction[J]. Heart Br Cardiac Soc, 2020, 106(15): 1160-1168. http://heart.bmj.com/content/early/2020/04/26/heartjnl-2019-316219
    [26]
    SARTIPY U, DAHLSTRÖM U, FU M, et al. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction[J]. JACC Heart Fail, 2017, 5(8): 565-574. doi: 10.1016/j.jchf.2017.05.001
    [27]
    TSUJI K, SAKATA Y, NOCHIOKA K, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study[J]. Eur J Heart Fail, 2017, 19(10): 1258-1269. doi: 10.1002/ejhf.807
    [28]
    GUO P, DAI J F, FENG C, et al. Special prognostic phenomenon for patients with mid-range ejection fraction heart failure: a systematic review and meta-analysis[J]. Chin Med J, 2020, 133(4): 452-461. doi: 10.1097/CM9.0000000000000653
    [29]
    TAKEI M, KOHSAKA S, SHIRAISHI Y, et al. Heart failure with midrange ejection fraction in patients admitted for acute decompensation: a report from the Japanese multicenter registry[J]. J Card Fail, 2019, 25(8): 666-673. doi: 10.1016/j.cardfail.2019.05.010
    [30]
    SAVARESE G, JONSSON Á, HALLBERG A C, et al. Prevalence of, associations with, and prognostic role of Anemia in heart failure across the ejection fraction spectrum[J]. Int J Cardiol, 2020, 298: 59-65. doi: 10.1016/j.ijcard.2019.08.049
    [31]
    LÖFMAN I, SZUMMER K, DAHLSTRÖM U, et al. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction[J]. Eur J Heart Fail, 2017, 19(12): 1606-1614. doi: 10.1002/ejhf.821
    [32]
    闫燕. 维持性血液透析患者不同射血分数范围值心力衰竭的临床特征及危险因素的比较和分析[D]. 天津: 天津医科大学, 2019.
    [33]
    BONSU K O, OWUSU I K, BUABENG K O, et al. Clinical characteristics and prognosis of patients admitted for heart failure: a 5-year retrospective study of African patients[J]. Int J Cardiol, 2017, 238: 128-135. doi: 10.1016/j.ijcard.2017.03.014
    [34]
    GAO F, WAN J D, XU B L, et al. Trajectories of waist-to-hip ratio and adverse outcomes in heart failure with mid-range ejection fraction[J]. Obes Facts, 2020, 13(3): 344-357. doi: 10.1159/000507708
    [35]
    MATSUSHITA K, HARADA K, MIYAZAKI T, et al. Effects of glycemic control on in-hospital mortality among acute heart failure patients with reduced, mid-range, and preserved ejection fraction[J]. Heart Vessels, 2018, 33(9): 1022-1028. doi: 10.1007/s00380-018-1152-2
    [36]
    FARMAKIS D, SIMITSIS P, BISTOLA V, et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome[J]. Clin Res Cardiol, 2017, 106(5): 359-368. doi: 10.1007/s00392-016-1063-0
    [37]
    WEBB J, DRAPER J, FOVARGUE L, et al. Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group[J]. Int J Cardiol Heart Vasc, 2018, 21: 1-6. http://www.sciencedirect.com/science/article/pii/S2352906718300034
    [38]
    FARRÉ N, LUPON J, ROIG E, et al. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain)[J]. BMJ Open, 2017, 7(12): e018719. doi: 10.1136/bmjopen-2017-018719
    [39]
    HSU J J, ZIAEIAN B, FONAROW G C. Heart failure with mid-range (borderline) ejection fraction: clinical implications and future directions[J]. JACC Heart Fail, 2017, 5(11): 763-771. doi: 10.1016/j.jchf.2017.06.013
    [40]
    VERGARO G, AIMO A, PRONTERA C, et al. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction[J]. Int J Cardiol, 2019, 296: 91-97. doi: 10.1016/j.ijcard.2019.08.040
    • Related Articles

  • Cited by

    Periodical cited type(4)

    1. 李丽芳，杨中男，刘力源，关郑军，徐艳，贺红丽，李燕萍. LncRNA LIPCAR在慢性心力衰竭患者外周血中的表达及临床意义. 宁夏医学杂志. 2024(09): 758-761 .
    2. 朱占占，孙雯雯，张申伟. 二甲双胍联合达格列净治疗2型糖尿病合并射血分数中间值心力衰竭患者的效果. 河南医学研究. 2022(21): 3980-3983 .
    3. 柳湘洁，刘晓霞. 沙库巴曲缬沙坦对射血分数中间值心力衰竭患者心功能及近期预后的影响. 临床和实验医学杂志. 2021(16): 1689-1692 .
    4. 左路广，黄冠杰，詹明华，李宝亮，张斌. 慢性心力衰竭并发感染患者病原学及脑钠肽变化研究. 实用临床医药杂志. 2021(19): 49-52 . 本站查看

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (215) PDF downloads (18) Cited by(5)
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return